ArticleCellular & molecular biology letters2025
Fusobacterium nucleatum-derived extracellular vesicles carrying virulence factor DNA trigger AIM2 inflammasome activation to facilitate UC progression.
Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- The Paradoxical Role of Pyroptosis in Gastrointestinal Cancers: From Molecular Mechanisms to Therapeutic Horizons.Biomedicines · 2026Review
- Macrophage pyroptosis in inflammatory bowel disease: mechanistic insights, pathological roles and treatment strategies.Frontiers in immunology · 2026Review
- Microbiota-immune crosstalk in the regulation of intestinal motility in constipation.Frontiers in microbiology · 2026Review
- The role ofJournal of oral microbiology · 2026Review
- Microbial mechanisms and therapeutic interventions in the periodontitis-inflammatory bowel disease axis: a comprehensive review.Journal of oral microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundImmune disorders and impaired intestinal barrier function resulting from dysbiosis of the intestinal flora play pivotal roles in the pathogenesis of ulcerative colitis (UC). Fusobacterium nucleatum (F. nucleatum, Fn) can secrete extracellular vesicles (EVs) that surmount the mucus layer, thereby contributing to UC progression. However, the underlying mechanisms and their clinical significance remain elusive.
methodsBioinformatics and clinical sample analysis were employed to explore the relationship between F. nucleatum and the absent in melanoma 2 (AIM2) inflammasome. Both in vivo and in vitro studies were performed to analyze the regulatory effects of extracellular vesicles released by F. nucleatum (Fn-EVs), which carry harmful molecules to the AIM2 inflammasome, as well as their ultimate role and clinical significance in UC progression.
resultsBioinformatics analysis showed upregulated expression of AIM2 and downstream pyroptosis-related genes in active UC, and that the AIM2 gene was linked to bacterial invasion and tight junctions. The clinical correlation between both F. nucleatum and its virulence proteins and the AIM2 inflammasome and downstream molecules was verified. Internalization of Fn-EVs by intestinal epithelial cells (IECs) triggered activation of the AIM2 inflammasome along with downstream pyroptosis molecules, resulting in damage to the intestinal barrier. Furthermore, we revealed that DNA components within Fn-EVs (Fn-EVs-DNA) play crucial roles in inducing these effects. Administration of DNase I, which targets Fn-EVs-DNA or A151 to block AIM2 inflammasome activation, effectively alleviated pyroptosis in IECs and restored gut barrier integrity, thereby mitigating UC progression.
conclusionsFn-EVs carrying the virulence factor DNA (Fn-DNA) are internalized by IECs to trigger AIM2 inflammasome-dependent pyroptosis and intestinal barrier disruption, eventually aggravating colitis. Targeting the Fn-EVs-DNA–AIM2 cascade may represent a promising therapeutic strategy for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.